டோனி மஜ்ஜுழ்ளி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ZEN Graphene Solutions Announces Ingestion Good Laboratory Practice Study for its Graphene-Based Compound ACCESSWIRE GUELPH, ON / ACCESSWIRE / May 3, 2021 / ZEN Graphene Solutions Ltd. ( ZEN or the Company ) (TSX-V:ZEN and OTC PINK:ZENYF), a Canadian, next-gen nanomaterials technology company, is pleased to announce that it will begin an ingestion Good Laboratory Practice (GLP) compliant safety study of its patent-pending, graphene-based compound following successful testing against Clostridium Difficile (C. Difficile) at the University of Manitoba under the supervision of Dr. George Zhanel, Professor, Department of Medical Microbiology and Infectious Disease and Director of the Canadian Antimicrobial Resistance Alliance. ZEN s compound was successfully tested against Vancomycin Resistant Enterococcus (VRE) previously by Dr. Tony Mazzulli, MD, FRCPC, Chief Microbiologist at Mount Sinai Hospital. VRE was one of the 13 forms of bacteria with antimicrobial resistance that ZEN s

United statesUnited kingdomGreg fentonTony mazzulliGeorge zhanelGraphene solutions ltdDepartment of medical microbiologyDrug administrationGood laboratory practiceUniversity of manitobaHealth canadaVenture exchangeRegulation services providerCanadian antimicrobial resistance allianceClostridium difficileMedical microbiology